Background: Cancer is the second cause of death after cardiovascular diseases worldwide. Tumor metastasis is the main cause of death in patients with cancer; therefore, unraveling the molecular mechanisms involved in metastasis is critical. Epithelial-mesenchymal transition (EMT) is believed to promote tumor metastasis. Based on the critical roles of long noncoding RNA-ATB (lncRNA-ATB) and SETD8 genes in cancer pathogenesis and EMT, in this study, we aimed to assess expression profile and clinicopathological relevance of these two genes in human gastric cancer. Materials and Methods: Quantitative real-time polymerase chain reaction was performed to assess these gene expressions in gastric cancer tissues and various cell lines. The associations between these gene expressions and clinicopathological characteristics were also analyzed. Results: Insignificant downregulation of lncRNA-ATB and significant upregulation of SETD8 in cancerous versus noncancerous gastric tissues were observed. Among different examined cell lines, all displayed both genes expression. Except for a significant inverse correlation between the expression levels of lncRNA-ATB and depth of invasion (T) and a direct association between SETD8 levels and advanced tumor grades, no significant association was found with other clinicopathological characteristics. Conclusion: lncRNA-ATB and SETD8 genes may play a critical role in gastric cancer progression and may serve as potential diagnostic/prognostic biomarkers in cancer patients.
Introduction
Gastric cancer is the second most frequent cause of cancer mortality in the world. [1] It is the second and fourth most common cancer in Iranian men and women, respectively, and the first leading cause of cancer deaths in Iran. [2] Ordinary treatments have no effect on improving the survival for most Iranian patients with gastric cancer because it is being diagnosed at an advanced stages of disease. [3] Epithelial-to-mesenchymal transition (EMT) is a process by which cell's features change from epithelial to mesenchymal, and it is known as a fundamental step for initiation of tumor cell metastasis. Various signaling pathways, transcriptional factors, and posttranscriptional regulatory networks such as long noncoding RNAs (lncRNAs) can motivate EMT process. [4] lncRNAs are a heterogeneous group of ncRNAs, which are larger than 200 nucleotides, with no protein-coding duty. [3, [5] [6] [7] These molecules are engaged
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For reprints contact: reprints@medknow.com in a broad range of biological and pathological processes such as cancer initiation, progression, [7] and metastasis. [5] Dysregulation of various lncRNAs in gastric cancer has been previously reported. [3, 8, 9] A transforming growth factor-beta (TGF-β)-induced lncRNA, lncRNA-ATB (lncRNA activated by TGF-β), is a lncRNA with 2741 nucleotides in length which is expressed from ENSG00000249549 gene on 14 chromosome. IncRNA-ATB stimulates EMT through competitively binding to mir-200 family, thus insulating them away from their mRNA targets: ZEB1 and ZEB2. [10, 11] Dysregulation of lncRNA-ATB has been reported in several cancer types. [10] [11] [12] [13] [14] [15] [16] SETD8 is a protein-coding gene encoding for an enzyme functioning as methyltransferase, in which its deregulation and role in cancer initiation, progression, and EMT has been also documented. [17, 18] Based on the important roles of lncRNA-ATB and SETD8 genes in cancer pathogenesis, in the current study, we aimed to assess expression profile of these two genes in human gastric cancer. Furthermore, we explored the association between these two genes expression and clinicopathological parameters of human gastric cancer samples.
Materials and Methods

Representative cancerous and noncancerous tissues
A total of 38 paired tissue specimens were tested for gene expression, of which 38 were cancerous and 38 were neighboring noncancerous samples of gastric from the same patients. In case of lncRNA-ATB gene, 37 paired samples were tested. Biological materials were provided by the Iran National Tumor Bank which is funded by the Cancer Institute of Tehran University, for Cancer Research. [19] [20] [21] All patients provided written informed permission to the Iran Tumoral Bank before the participation, and all experimental procedures were accepted by the Ethics Committee of Isfahan University of Medical Sciences. The clinical staging of the cancerous specimens was done based on the seventh edition of the American Joint Committee on Cancer (AJCC) staging manual for stomach. [22] 
Cell lines and cell cultivation
The human liver hepatocellular carcinoma cell line (HepG2) was cultivated in RPMI-1640 (Gibco Life Technologies, Karlsruhe, Germany), supplemented with 10% fetal calf serum, 100 U/ml penicillin, and 10 µg/ml streptomycin. The human embryonic kidney 293 cells, human pulmonary carcinoma cells (A542), human breast cancer cell (MCF7), and human umbilical vein endothelial cells (HUVECs) were cultivated in the high glucose DMEM (Gibco Life Technologies, Karlsruhe, Germany), enriched with 15% fetal calf serum, 100 U/ml penicillin, and 10 µg/ml streptomycin.
Total RNA isolation and cDNA synthesis
Total RNA was extracted from powdered gastric cancer tissues using TRIzol ® Reagent (Invitrogen, Carlsbad, California, United States) as stated in manufacturer's protocol (Trizol Reagent. Catalog numbers: 15,596-026 and 15,596-018). One percent agarose gel electrophoresis was used to determine the integrity of the RNA. Nanodrop instrument (Nanolytik, Düsseldorf, Germany) was used for determining RNA concentration by measuring optical density at 260 nm. DNase treatment was performed using DNase set (Fermentas, Vilnius, Lithuania) for erasing genomic DNA. cDNA synthesis was performed using PrimeScriptTM RT reagent Kit (TaKaRa, Kusatsu, Shiga, Japan) as stated in manufacturer's protocol.
Quantitative real-time polymerase chain reaction and DNA sequencing
The expression level of lncRNA-ATB and SETD8 genes was tested by quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) in comparison to β-Glucuronidase (GUSB) as a reference gene. [23] The primers for the target genes were designed with GeneRunner software, version 4.0, and tested by basic local alignment search tool (BLAST [http://blast. ncbi.nlm.nih.gov/Blast.cgi]) for unity attachment to genome. Primers were as follows for lncRNA-ATB forward: ACGTCTTGTGCTTGGATCCTA, for lncRNA-ATB reverse: CGCAAATACAGACAGGTCACC, with an amplicon size of 227 bp for lncRNA-ATB, primers for SETD8 forward: CGAGCTGCAGTCTGAAGAAAG and for SETD8 reverse: TTTCTTGGCGTCGGTGATC with an amplicon size of 184 bp for SETD8. Real-time PCR was done with RealQ Plus ×2 Master Mix, green (high ROX) (AMPLIQON, Odense M, Denmark) by an Applied Biosystems StepOnePlus™ instrument. The PCR amplification conditions included of first denaturation at 95°C for 10 min, 40 cycles of denaturation at 95°C for 15 s, annealing at 61°C for lncRNA-ATB and SETD8 and at 60°C for GUSB genes for 60 s, then extension for 15 s at 72°C. Moreover, to be ensured that the actual genes of interest (lncRNA-ATB and SETD8) are getting specifically amplified, the PCR products of some samples were sequenced with an Applied Biosystems 3730XL sequencer (Macrogen, Seoul, South Korea).
Statistical gene expression analysis
The ΔC t method (C t of gene of interest-C t of housekeeping gene) was used to quantify the relative levels of gene expression. All experiments were done at least two or three times and expressed as means ± standard error of mean. To determine normal distribution of samples, KolmogorovSmirnov test was performed. Student's t-test, analysis of variance, and Chi-square were done to examine statistical significance. SPSS software, version 16.0, was used for statistical analyses and P < 0.05 was considered statistically significant.
Results
Optimization of real time-polymerase chain reaction
Prior to the quantitative analysis, optimization procedures were done to achieve a specific amplicon for lncRNA-ATB and SETD8 genes in both conventional and real-time RT-PCR reactions on cancerous gastric tissue specimens. As it was demonstrated in previous studies that both lncRNA-ATB and SETD8 are expressed in MCF-7 breast cancer cell line, [11, 18] we applied the cDNA of MCF-7 cell line for optimization procedures. Agarose gel electrophoresis of the amplified product of lncRNA-ATB and SETD8 demonstrated a specific band with the expected sizes for both genes. In addition, in real time process, unique melting curves without primer dimers for each of the examined genes confirmed the specificity of amplicons (data not shown). BLAST of the results of PCR product sequencing against human transcripts showed 100% identity with corresponding transcripts.
Expression of long noncoding RNA-ATB and SETD8 genes in various cultivated cells, human cancerous, and noncancerous gastric specimens
According to RT-PCR results, five of five examined cell lines displayed lncRNA-ATB and SETD8 expressions [ Figure 1 ]. To determine the expression levels of lncRNA-ATB and SETD8 genes in human gastric tissues, cDNAs were synthesized for all specimens and real-time PCR was performed using specific primers for lncRNA-ATB, SETD8, and GUSB genes. Relative expression of target genes was detected by subtracting its C t value to that of the GUSB gene. The results of real-time qRT-PCR experiments demonstrated that while the relative expression of lncRNA-ATB gene was high in some examined tumor tissues, its expression was low in some others. Figure 2 shows the relative mean expression of lncRNA-ATB gene in cancerous and noncancerous gastric tissue samples. As expected from the results, statistical analyses failed to show any significant difference between the lncRNA-ATB gene expression of cancerous specimens and that of the noncancerous ones. Relative quantitation of the expression levels of SETD8 in gastric adenocarcinomas showed that the relative levels of its transcripts were significantly increased (P = 0.018) in cancerous tissues compared with adjacent noncancerous tissues: 0.88 ± 0.66 versus 2.78 ± 0.59, respectively, as shown in Figure 3 .
Association between long noncoding RNA-ATB and SETD8 expression and clinicopathological characters in gastric cancer
To examine the clinical consequences of the lncRNA-ATB and SETD8 expressions, the correlation between clinicopathological status of gastric cancerous specimens and levels of lncRNA-ATB and SETD8 expression was calculated. Except for a significant inverse correlation between the expression levels of lncRNA-ATB and depth of invasion (T) (P = 0.0002), no significant association was found with other clinicopathological characteristics for both examined genes (data not shown).
As in other previous studies in which lncRNA expression in cancerous tissues was classified as high or low according to the median value of lncRNA expression, gastric cancer patients were further divided into two groups based on the median value of relative gene expression in cancer tissues. The correlations between the lncRNA-ATB and SETD8 expression levels and the clinicopathological characters of gastric cancer patients are summarized in Tables 1 and 2 . The results suggested a relationship between high SETD8 level and advanced tumor grades (P = 0.01). Overall, no significant association was observed between lncRNA-ATB and SETD8 expression level and any other clinicopathological factors.
Discussion
In the current study, we examined the lncRNA-ATB gene expression profile in various cultivated cells and a series of cancerous and noncancerous gastric tissue specimens. Real-time qRT-PCR showed that lncRNA-ATB was expressed in all examined cell lines. In gastric tissue samples, cancerous tissues had relatively lower lncRNA-ATB expression levels than noncancerous ones, although the difference was not statistically significant. We also revealed that lncRNA-ATB levels were inversely associated with depth of invasion (T). A previous report by Saito et al., [14] in patients with gastric cancer, showed that high level of lncRNA-ATB expression was associated with vascular invasion, lower survival rates, and poorer prognosis. They also reported lncRNA-ATB expression levels in all eight examined GC lines. A critical difference between the Saito's study and our own is that they only collected cancerous tissue samples, and not any noncancerous gastric tissues. Yuan et al. [11] discovered the lncRNA-ATB gene and measured its expression level in a set of hepatocellular carcinoma (HCC) tissues. Their result showed that lncRNA-ATB transcript level is higher in the HCC tissues compared to the paired adjacent noncancerous hepatic tissues. There was also a direct correlation between lncRNA-ATB levels and the metastasis-related clinicopathological characteristics of HCC samples. They also assessed the gene expression in SMMC-7721 hepatoma cells, the normal liver cell line QSG-7701, breast cancer cell line MCF7, and colorectal cancer cell line SW480. All cells had basic levels of lncRNA-ATB expression before treatment with TGF-β and showed a significant increase in its levels after TGF-β treatments, further confirming that lncRNA-ATB is regulated by TGF-β. lncRNA-ATB expression has also been evaluated in patients with colorectal cancer. Its high expression levels was associated with greater tumor size, depth of tumor invasion (T), lymphatic invasion, vascular invasion, lymph node metastasis, hematogenous metastasis, and poorer outcomes. [12] In a recent report, high lncRNA-ATB expression level was documented in trastuzumab-resistant SKBR-3 cells and breast cancer tissues. Trastuzumab resistance and invasion-metastasis cascade in breast cancer is mediated by sponging role of lncRNA-ATB for miR-200c and thus increasing ZEB1 and ZNF-217 and then inducing EMT. [15] The first study which reported downregulation of lncRNA-ATB in tumoral tissues was published on 2015.
[13] A set of pancreatic cancerous and adjacent noncancerous pancreatic tissues were included in the study and the results showed that lncRNA-ATB transcript level was significantly lower in pancreatic cancerous tissues compared with the paired adjacent noncancerous tissues. Their results also showed that lncRNA-ATB expression levels were significantly and inversely correlated with lymphatic metastasis, neural invasion, and clinical stage. However, lncRNA-ATB expression did not correlate with other clinicopathological characteristics. lncRNA-ATB expression in colon cancer tissues was reported to be significantly higher than matched adjacent mucosa. There was also a direct association between levels of lncRNA-ATB and pN and AJCC stages. Overall survival and disease-free survival in cases with both high lncRNA-ATB expression and low E-cadherin expression were also significantly lower than patients with low lncRNA-ATB levels. Evaluation of expression of lncRNA-ATB in three high-invasive colon cancer cells and three low-invasive colon cancer cells showed higher expression levels in metastatic cell lines. [16] Taken together, our result on gastric cancer is more consistent with the previously published report by Qu et al. [13] who reported a remarkably downregulated levels of lncRNA-ATB in pancreatic tissues. As Qu et al. commented, these findings revealed that lncRNA-ATB might act as an oncogene or cancer suppressor in a tissue-dependent manner. [13] The histone methyltransferase (HMTs) family of proteins consists of enzymes that methylate lysine or arginine residues on histone tails as well as other proteins. The role of many HMTs in tumorigenesis and progression of human cancers have been documented. [24] As a member of HMTs, SETD8 has a well-defined role in the TP53 pathway, thus regulating cell proliferation and genome stability.
[25] SETD8 monomethylates protein P53 at lysine 382 and represses its proapoptotic and cell cycle arrest functions. [25] The role of SETD8 in promoting EMT and metastasis has been well documented. [18] Expression analysis of SETD8 in a set of breast tissues revealed a positive correlation between higher SETD8 levels and metastatic capacity of breast cancer tissues. [18] In a study by Takawa et al., [17] overexpression of SETD8 in numerous types of cancers including bladder cancer, non-small cell lung carcinoma, small cell lung carcinoma, chronic myelogenous leukemia, HCC, and pancreatic cancer has been reported. In the current study, we observed a significantly higher expression of SETD8 in gastric cancer tissues compared to noncancerous ones. Our data are in agreement with the proliferation-promoting role of SETD8 in other cancer types. [17, 18] An association between SETD8 expression levels and higher tumor grades was observed in our study. In the same vein, SETD8 expression level has been correlated with the grade of malignancy in bladder cancer. [17] Several studies have assessed the cancer-predisposing functions of a microRNA binding site within 3'UTR of SETD8 (rs16917496). [26] [27] [28] [29] [30] It was shown in HCC and non-small cell lung cancer that the SETD8 CC genotype is correlated with reduced SET8 protein levels and longer survival. [29, 31] 
Conclusion
We investigated the clinicopathological relevance of two EMT-related genes: lncRNA-ATB and SETD8 in a series of gastric cancer tissues. Our study demonstrated that lncRNA-ATB expression was partly decreased in gastric cancer and inversely correlated with the depth of invasion (T). We further showed that SETD8 level was augmented in gastric cancerous tissues and this elevation was associated with higher tumor grades. These data showed that lncRNA-ATB and SETD8 genes may play a critical role in gastric cancer progression and may serve as potential diagnostic/prognostic biomarkers in cancer patients. However, further studies are needed to reveal the molecular mechanisms of lncRNA-ATB and SETD8 in gastric cancer pathogenesis.
